Aug 17 (Reuters) – AstraZeneca on Monday said it is discontinuing a late stage trial that tested volrustomig plus chemotherapy in patients with metastatic non-small cell lung cancer.
The decision followed a recommendation from an independent data monitoring committee, which found the volrustomig combination was unlikely to meet either of its primary endpoints of progression-free survival or overall survival in patients with tumours without the PD-L1 protein.
The discontinuation adds to a run of unexpected trial failures this year that have fuelled concerns about the the drugmaker’s pipeline.
AstraZeneca said the safety profile of the drug, in combination with chemotherapy, was consistent with the known profiles of the individual medicines, with no new safety signals identified.
(Reporting by Raechel Thankam Job in Bengaluru; Editing by Janane Venkatraman and Nivedita Bhattacharjee)
